Physician profile
Simon Chen
NPI 1982794525
$1,898.51
in general payments reported to CMS, 2019-2025
15 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $774 · 2020: $82.49 · 2021: $244 · 2022: $281 · 2023: $113 · 2024: $178 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497 · Consulting Fee: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $496.93 |
| Consulting Fee | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $403.80 | 2019-2025 | Dailies Total1, Total30 |
| Coopervision INC. | $273.26 | 2019-2025 | Myday Contact Lens |
| Visioneering Technologies, INC. | $195.70 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $193.18 | 2019 | |
| Sight Sciences, INC. | $155.51 | 2020-2021 | |
| Maculogix, INC. | $150.89 | 2019 | |
| Biotissue Holdings INC. | $150.27 | 2024 | |
| Alcon Research LLC | $94.44 | 2019 | |
| Visionix USA, INC | $71.43 | 2022 | |
| Optovue, INC. | $57.19 | 2019 | |
| Abbvie INC. | $52.58 | 2022-2023 | Vuity |
| Tarsus Pharmaceuticals, INC. | $34.89 | 2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $34.43 | 2022 | |
| Bausch & Lomb Americas INC. | $20.78 | 2025 | Xiidra |
| Optos, INC. | $10.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.